No Data
Give the Gift of Emotional Growth This Holiday Season
Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences
Craig-Hallum Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating
Express News | Skye Bioscience Inc - Expects Interim Data for Cbeyond Phase 2 Trial in Q2 2025
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
Oppenheimer Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Maintains Target Price $21
No Data
No Data